Multiple Sclerosis Clinical Trials in Phoenix

New Research Options for RRMS, SPMS, PPMS, and Progressive MS at CNS and Arizona Neuroscience Research

Current Studies - Arizona Neuroscience Research - Trials

Multiple sclerosis, also known as MS, is a complex neurological disease that can affect vision, strength, sensation, balance, walking, bladder function, fatigue, cognition, and quality of life. For many patients, MS is not just one diagnosis. It is a lifelong condition that may change over time.

Some patients have relapsing-remitting multiple sclerosis, also called RRMS. Others develop secondary progressive multiple sclerosis, also called SPMS. Some patients are diagnosed with primary progressive multiple sclerosis, also called PPMS. Each form of MS can look different, progress differently, and require a different treatment strategy.

At Center for Neurology and Spine in Phoenix, Arizona, patients with multiple sclerosis can receive neurological evaluation, treatment planning, MRI review, symptom management, and ongoing care. Through Arizona Neuroscience Research, patients may also have opportunities to learn about clinical trials for multiple sclerosis, including studies evaluating investigational therapies, real-world treatment experience, and new approaches for relapsing and progressive forms of MS.

If you are searching for multiple sclerosis doctor Phoenix, MS specialist Arizona, MS clinical trials Phoenix, multiple sclerosis research Arizona, progressive MS treatment options Phoenix, RRMS clinical trials Arizona, SPMS trials Phoenix, PPMS clinical trials Arizona, or neurologist Phoenix AZ, this guide explains what MS clinical trials are, why they matter, and which MS studies are currently enrolling or preparing to enroll through Arizona Neuroscience Research.

What Is Multiple Sclerosis?

Multiple sclerosis is a chronic disease of the central nervous system, which includes the brain, spinal cord, and optic nerves. In MS, the immune system attacks myelin, the protective covering around nerve fibers. This can disrupt communication between the brain and the rest of the body.

MS symptoms may include:

Vision changes

Numbness or tingling

Weakness

Balance problems

Walking difficulty

Fatigue

Pain

Muscle stiffness or spasticity

Bladder symptoms

Cognitive changes

Heat sensitivity

Dizziness

Coordination problems

Symptoms can come and go, worsen during relapses, or gradually progress over time. Because MS affects each person differently, individualized neurological care is essential.

Types of Multiple Sclerosis

Relapsing-Remitting MS

Relapsing-remitting MS is the most common form of MS. Patients experience relapses or flare-ups, followed by periods of partial or complete recovery. Relapses may involve new or worsening neurological symptoms lasting days to weeks.

Secondary Progressive MS

Secondary progressive MS may develop after an earlier relapsing course. In SPMS, patients may experience gradual worsening of disability over time, with or without relapses. Some patients have active SPMS with relapses or MRI activity. Others have non-active SPMS, where progression occurs without clear relapses.

Primary Progressive MS

Primary progressive MS involves gradual worsening from the beginning of the disease, without early relapses and remissions. PPMS can be especially challenging because treatment options have historically been more limited compared with relapsing MS.

Why MS Clinical Trials Matter

MS treatment has changed dramatically over the past several decades. Today, there are more disease-modifying therapies than ever before for relapsing forms of MS. However, important needs remain.

Patients and researchers are still looking for better ways to:

Reduce relapses

Slow disability progression

Protect brain and spinal cord tissue

Improve treatment convenience

Understand long-term safety

Treat progressive MS more effectively

Improve quality of life

Identify which patients respond best to which therapy

Clinical trials are one way new treatment approaches are studied. A clinical trial may evaluate an investigational medication, compare different methods of administration, collect real-world data, or study long-term treatment experience.

Participation in a clinical trial is voluntary. Not every patient will qualify, and not every trial is appropriate for every patient. Eligibility depends on the study protocol, diagnosis, age, medical history, prior treatments, MRI findings, current disease activity, safety criteria, and other factors.

MS Research in Phoenix Through CNS and Arizona Neuroscience Research

Center for Neurology and Spine provides neurological care for patients with MS and other neurological disorders. Arizona Neuroscience Research offers opportunities for eligible participants to learn about clinical trials in Phoenix.

This combination is important because MS care and MS research often work together. A patient may need careful diagnosis, treatment planning, MRI review, symptom management, and education before determining whether a research study might be appropriate.

Patients may contact Arizona Neuroscience Research to ask about current MS trial availability, screening, eligibility, and next steps.

Current and Upcoming MS Trials at Arizona Neuroscience Research

Arizona Neuroscience Research is now enrolling or preparing to enroll participants in several MS studies. These include studies for relapsing MS, secondary progressive MS, primary progressive MS, and real-world treatment experience.

Frexcite EFC18098
Frexalimab in Relapsing and Secondary Progressive Multiple Sclerosis

Arizona Neuroscience Research is now enrolling participants in the Frexcite clinical trial, a Phase 3 study investigating frexalimab for adults with multiple sclerosis.

About the Study

Frexcite is a bridging study evaluating pharmacokinetics and safety of subcutaneous versus intravenous administration of frexalimab in adults with MS. Subcutaneous administration means medication is given under the skin. Intravenous administration means medication is given through a vein.

This matters because how a medication is administered can affect patient experience, clinic workflow, convenience, dosing, monitoring, and how the body absorbs and processes the medication.

Frexalimab is investigational in this context. Trial participation does not guarantee benefit, and eligibility must be confirmed through the study team.

Who May Be Eligible

Eligibility depends on the current protocol and approved study materials. Patients with relapsing MS or certain secondary progressive MS presentations may ask whether screening is appropriate.

Sponsor

Sanofi

Patient Call to Action

Patients interested in learning more can visit the Volunteer Today page or contact Arizona Neuroscience Research for current criteria.

Why This Trial May Interest Patients

Frexcite may be of interest to patients who want to learn about investigational MS research involving frexalimab and administration options. Patients should discuss current MS therapy, risks, benefits, and study requirements with their neurologist and the research team before making any decision.

Enable TG1101-RMS406
Real-World Experience with BRIUMVI in Relapsing MS

Arizona Neuroscience Research is now enrolling participants in the Enable clinical trial, also known as TG1101-RMS406.

About the Study

Enable is a Phase 4 observational registry study evaluating real-world experience with BRIUMVI, also known as ublituximab-xiiy, in adults with relapsing multiple sclerosis.

This registry collects data on safety, effectiveness, and patient experience in routine clinical practice over 96 weeks. Unlike a traditional randomized placebo-controlled trial, an observational registry is designed to learn from real-world treatment patterns and outcomes.

Who May Be Eligible

Adults with relapsing forms of multiple sclerosis who are prescribed BRIUMVI may be eligible. Final eligibility depends on approved study materials and screening.

Sponsor

TG Therapeutics

Patient Call to Action

Patients interested in learning more can visit the Volunteer Today page or contact Arizona Neuroscience Research.

Why This Trial May Interest Patients

Enable may be relevant for patients who have already been prescribed BRIUMVI and want to contribute to research about real-world MS treatment experience. Real-world studies can help researchers understand how therapies perform outside of the controlled environment of earlier-stage trials.

Primrose ZB020-03-001
Orelabrutinib in Primary Progressive MS

Arizona Neuroscience Research is now enrolling participants in the Primrose clinical trial, also known as ZB020-03-001.

About the Study

Primrose is a global, randomized, double-blind, placebo-controlled Phase 3 trial evaluating the efficacy and safety of orelabrutinib in adults with primary progressive multiple sclerosis.

Primary progressive MS can be difficult to treat because progression occurs gradually from disease onset. Research in PPMS is important because patients need more options aimed at slowing disability progression and preserving function.

Who May Be Eligible

Adults ages 18 to 60 with primary progressive MS may be eligible. Final eligibility depends on approved study materials, screening, diagnosis, medical history, and protocol criteria.

Sponsor

Zenas BioPharma

Patient Call to Action

Patients interested in learning more can visit the Volunteer Today page or contact Arizona Neuroscience Research.

Why This Trial May Interest Patients

Primrose may be relevant for adults with PPMS who want to explore whether they may qualify for a Phase 3 clinical trial studying an investigational therapy. Patients should speak with their neurologist and the research team to understand the study design, potential risks, time commitment, and eligibility requirements.

Monarch ZB020-03-002
Orelabrutinib in Non-Active Secondary Progressive MS

Arizona Neuroscience Research is now enrolling participants in the Monarch clinical trial, also known as ZB020-03-002.

About the Study

Monarch is a global, randomized, double-blind, placebo-controlled Phase 3 trial evaluating the efficacy and safety of orelabrutinib in adults with non-active secondary progressive multiple sclerosis.

Non-active SPMS can be challenging because patients may continue to worsen even without obvious relapses or new MRI activity. Research in this area is important because progressive disability can affect walking, independence, work, energy, cognition, and daily function.

Who May Be Eligible

Adults with non-active secondary progressive MS may be eligible. Final eligibility depends on approved study materials and screening.

Sponsor

Zenas BioPharma

Patient Call to Action

Patients interested in learning more can visit the Volunteer Today page or contact Arizona Neuroscience Research.

Why This Trial May Interest Patients

Monarch may be relevant for patients with SPMS who are experiencing progression without clear relapses. Patients should not assume they qualify based on diagnosis alone. The research team must review the protocol criteria, disease course, medications, MRI history, and safety requirements.

Remaster CLOU064P12301
Remibrutinib in Secondary Progressive MS

Arizona Neuroscience Research is preparing to enroll participants in the Remaster clinical trial, also known as CLOU064P12301.

About the Study

Remaster is a randomized, double-blind, placebo-controlled Phase 3 trial evaluating remibrutinib in adults with secondary progressive multiple sclerosis.

Secondary progressive MS remains an important area of MS research because many patients continue to experience gradual worsening despite fewer relapses. Studies like Remaster are designed to evaluate whether investigational therapies may help address progression in SPMS.

Who May Be Eligible

Adults with secondary progressive MS may be eligible. Because enrollment status and criteria may change, patients should contact Arizona Neuroscience Research for current status and screening information.

Sponsor

Novartis

Patient Call to Action

Patients interested in learning more can visit the Volunteer Today page or contact Arizona Neuroscience Research for current availability.

Why This Trial May Interest Patients

Remaster may be relevant for adults with SPMS who are interested in learning about research options involving remibrutinib. Participation depends on study status, inclusion criteria, exclusion criteria, safety screening, and discussion with the research team.

How to Know Whether an MS Trial Might Be Right for You

A clinical trial may be worth asking about if you have MS and want to learn whether research participation is an option. However, a trial is not automatically the right fit for every patient.

Factors that may affect eligibility include:

Type of MS

Age

Disease duration

Relapse history

MRI findings

Current disability level

Current MS medications

Prior MS treatments

Other medical conditions

Infection risk

Pregnancy status or family planning

Lab results

Vaccination history

Ability to attend study visits

Study-specific inclusion and exclusion criteria

The only way to know whether you qualify is to complete the screening process through the research team.

What Happens During MS Trial Screening?

Clinical trial screening is designed to determine whether a patient meets the study criteria and whether participation is appropriate and safe.

Screening may include:

Review of diagnosis

Review of MS history

Medication history

Neurological examination

MRI review or new MRI

Blood work

Pregnancy testing when applicable

Review of other medical conditions

Review of infection history

Review of vaccines

Discussion of study visits

Informed consent process

The informed consent process is important. Before joining a trial, participants should understand the study purpose, procedures, possible risks, possible benefits, alternatives, visit schedule, costs, compensation if applicable, and privacy protections.

Questions to Ask Before Joining an MS Clinical Trial

Patients should feel comfortable asking questions before joining a study.

Helpful questions include:

What is the purpose of this study?

Is the medication investigational?

Is there a placebo?

How long does the study last?

How often are visits required?

Will I need MRI scans?

Will I need blood work?

What are the possible risks?

What side effects are known so far?

Can I stay on my current MS medication?

What happens if my MS worsens?

Can I leave the study?

Will my insurance be billed?

Is compensation available?

Who do I call if I have symptoms?

How will my neurologist be updated?

Asking questions is not a problem. It is part of good clinical research participation.

Why Progressive MS Research Is So Important

Progressive MS can be especially frustrating. A patient may not have obvious relapses, but walking, balance, fatigue, cognition, or independence may slowly worsen. Patients may feel overlooked because much of MS treatment history has focused on relapsing disease.

Research in PPMS and SPMS matters because progressive disease affects daily life in practical ways.

Patients may struggle with:

Walking distance

Leg weakness

Balance

Falls

Fatigue

Cognitive slowing

Bladder symptoms

Spasticity

Pain

Work limitations

Need for mobility aids

Loss of independence

Clinical trials for PPMS and SPMS are important because they may help researchers understand how to slow progression, measure disability changes, and evaluate new treatment pathways.

Why Relapsing MS Research Still Matters

Relapsing MS research remains important because patients need therapies that reduce relapses, limit MRI activity, preserve brain volume, protect function, and fit into real life.

Patients may also need more information about long-term safety, real-world experience, treatment sequencing, infusion versus injection options, and patient-reported outcomes.

Studies like Enable can help collect real-world information from patients treated in routine practice. Studies like Frexcite can help evaluate administration methods and how an investigational therapy behaves in the body.

MS Care Beyond Medication

Medication is only one part of MS care. Patients also need support for symptoms and daily function.

CNS evaluates and helps manage symptoms such as:

Fatigue

Pain

Numbness

Tingling

Weakness

Gait problems

Balance issues

Spasticity

Bladder complaints

Cognitive changes

Dizziness

Heat sensitivity

Migraine overlap

Neuropathy symptoms

A complete MS care plan may include disease-modifying therapy, symptom management, rehabilitation, lifestyle planning, imaging surveillance, lab monitoring, and second opinions when needed.

Arizona-Specific MS Considerations

Living with MS in Arizona can create unique challenges. Heat sensitivity is common in MS, and Phoenix summers can make fatigue, weakness, vision symptoms, and walking problems feel worse.

Arizona patients may need practical strategies such as:

Avoiding outdoor activity during peak heat

Using cooling vests or cooling towels

Planning errands early in the morning

Staying hydrated

Exercising indoors

Using shaded parking when possible

Monitoring fatigue during summer months

Discussing heat-related symptom worsening with a neurologist

Planning travel carefully

Heat sensitivity does not always mean new MS damage is occurring, but worsening symptoms should still be discussed with a clinician, especially if they are new, severe, or persistent.

Why Choose CNS and Arizona Neuroscience Research for MS Care and Trials in Phoenix?

Patients choose Center for Neurology and Spine and Arizona Neuroscience Research because they offer a combination of clinical neurology care and research access in Phoenix.

CNS and ANR provide:

Multiple sclerosis evaluation

MS treatment planning

MRI review

Neurological examination

Symptom management

Clinical trial education

Research screening

Opportunities for eligible participants to learn about active and upcoming studies

Care for relapsing and progressive MS

Local access for Phoenix and Valley patients

For patients across Phoenix, Scottsdale, Tempe, Mesa, Chandler, Gilbert, Glendale, Peoria, Paradise Valley, Ahwatukee, and surrounding Arizona communities, local access to MS research may make it easier to explore study options without traveling out of state.

Frequently Asked Questions

Does CNS treat multiple sclerosis?

Yes. Center for Neurology and Spine evaluates and manages multiple sclerosis, including relapsing MS, progressive MS symptoms, MRI review, treatment planning, and symptom management.

Does Arizona Neuroscience Research offer MS clinical trials?

Yes. Arizona Neuroscience Research is enrolling or preparing to enroll participants in multiple MS studies, including Frexcite, Enable, Primrose, Monarch, and Remaster.

What is Frexcite?

Frexcite is a Phase 3 study evaluating subcutaneous versus intravenous administration of frexalimab in adults with multiple sclerosis.

What is Enable?

Enable is a Phase 4 observational registry collecting real-world data on adults with relapsing MS who are prescribed BRIUMVI.

What is Primrose?

Primrose is a Phase 3 study evaluating orelabrutinib in adults with primary progressive multiple sclerosis.

What is Monarch?

Monarch is a Phase 3 study evaluating orelabrutinib in adults with non-active secondary progressive multiple sclerosis.

What is Remaster?

Remaster is a Phase 3 study evaluating remibrutinib in adults with secondary progressive multiple sclerosis.

Do I have to stop my current MS medication to join a trial?

Do not stop any medication unless instructed by your treating clinician or the study team. Trial requirements vary by protocol.

Can I join a trial if I have progressive MS?

Possibly. Several studies focus on PPMS or SPMS, but eligibility depends on the specific study criteria and screening results.

Is clinical trial participation voluntary?

Yes. Participation is voluntary. Patients can ask questions, review the informed consent document, and decide whether participation is right for them.

How do I learn if I qualify?

Contact Arizona Neuroscience Research through the Volunteer Today page or speak with the research team for current criteria and screening steps.

Schedule an MS Evaluation or Ask About MS Research in Phoenix

If you have multiple sclerosis or symptoms that may suggest MS, Center for Neurology and Spine can help with neurological evaluation, MRI review, diagnosis, treatment planning, and symptom management.

If you are interested in MS clinical trials in Phoenix, Arizona Neuroscience Research can provide information about current and upcoming studies, including Frexcite, Enable, Primrose, Monarch, and Remaster.

Visit cnsofaz.com for neurology care or the Volunteer Today page to ask about research opportunities.

SEO Meta Section

Meta Title

Multiple Sclerosis Clinical Trials in Phoenix AZ
CNS and Arizona Neuroscience Research MS Studies

Meta Description

Learn about multiple sclerosis care and MS clinical trials in Phoenix, including Frexcite, Enable, Primrose, Monarch, and Remaster studies for RRMS, SPMS, PPMS, and relapsing MS.

Suggested URL Slug

multiple-sclerosis-clinical-trials-phoenix-az

Primary Keywords

multiple sclerosis clinical trials Phoenix

MS clinical trials Arizona

multiple sclerosis doctor Phoenix

MS specialist Arizona

progressive MS trials Phoenix

relapsing MS research Arizona

Phoenix MS research

Arizona Neuroscience Research MS trials

Secondary Keywords

RRMS clinical trials Phoenix

SPMS clinical trials Arizona

PPMS clinical trials Phoenix

Frexcite trial Phoenix

frexalimab MS trial Arizona

Enable BRIUMVI registry Phoenix

Primrose orelabrutinib PPMS

Monarch orelabrutinib SPMS

Remaster remibrutinib SPMS

MS neurologist Phoenix AZ

multiple sclerosis treatment Phoenix

Local SEO Keywords

MS doctor North Phoenix

MS specialist Biltmore Phoenix

multiple sclerosis care Scottsdale

MS clinical trials Tempe

MS research Mesa AZ

MS neurologist Chandler

multiple sclerosis doctor Gilbert

MS care Glendale AZ

MS specialist Peoria AZ

MS treatment Paradise Valley

MS clinical trials Ahwatukee